Business Wire

CA-WORKATO

Share
Workato Announces $110M at $1.7B Valuation to Transform How Enterprises Work with Integration-Led Automation

Workato , the leader in integration-led automation, today announced $110 million in Series D funding led by global investment firm Altimeter Capital alongside Insight Partners. Pauline Yang, partner at Altimeter Capital, will join Workato's board of directors as an observer. Existing investors, Redpoint Ventures and Battery Ventures, also participated in the round. This investment brings the total capital raised by the company to over $221 million and values Workato at $1.7 billion.

“There’s been explosive growth in business apps and cloud technologies, but their potential remains largely untapped. This explosion has created tech chaos with siloed data, fragmented business processes and broken UX,” said Vijay Tella, CEO and co-founder of Workato. “Workato addresses this with a single platform built for business and IT that easily, reliably, and securely connects their apps, data, and business processes so teams can work smarter and faster. With our new investment, we’re looking forward to helping other companies around the world use integration-led automation to transform how they work."

Shaping the Future of Work for the Enterprise

Workato allows companies to maximize the value of their apps, data and people by making it easy to integrate disconnected data and applications, and securely automate workflows to accelerate business outcomes. Previously, businesses attempted to achieve this using a patchwork of different technologies, including Robotic Process Automation (RPA), Integration Platform as a Service (iPaaS), business process management (BPM) and chatbots. This legacy approach requires teams of specialists and results in fragile application and workflow connections that are insecure and hard to scale. Workato’s no code/low code platform combines enterprise-grade integration and automation capabilities in a single platform that is trusted by IT and easy to use for the business. With Workato, IT and business teams can more easily collaborate to rapidly integrate data, processes, applications and user experiences in almost any combination without compromising security and governance.

Workato’s integration-led automation platform is used by more than 7,000 businesses, including Broadcom, Coupa, Intuit, Autodesk, Nutanix and Rapid7. With a rapidly growing community of over 70,000 users who can create automations from scratch or get started faster with over 500,000 pre-built automation “recipes,” Workato’s cloud-native platform automates processes in marketing, sales, finance, HR, IT, and many other business areas so that teams can work faster and smarter.

A Record-Breaking Year Accelerated by COVID-19 and the Digital Imperative

Since raising its $70 million Series C round in late 2019, Workato has:

  • Nearly tripled its revenue and customer base
  • Increased workflows in production per customer threefold and workloads per customer fourfold across data integration, process automation, and chatbots
  • Seen the customer and partner community create over 500 connectors to new apps and systems each month
  • Ranked 96th in North America and 17th in the Bay Area in Deloitte’s 2020 Technology Fast 500
  • Named as a leader for the past three years in Gartner’s Magic Quadrant for Enterprise iPaaS , Workato is the only automation platform vendor that is also a leader in integration. Workato is also the only Automation vendor recognized in The Forrester Wave™: Strategic iPaaS and Hybrid Integration Platforms report, further underpinning Workato's integration-led approach to automation
  • Experienced 200% growth in new partners, and forged new technology partnerships with companies like Snowflake, Adobe, OutSystems, Workplace from Facebook and more

Workato will use the new investment to double down on its product innovation and technology development, continuing to lead the movement toward integration-led automation. The company will also expand its customer success program and launch its first user conference in 2021. Additionally, it will invest significantly in scaling teams in the U.S. and internationally in EMEA and APAC.

"The explosion of SaaS apps and increasingly complex hybrid environments have accelerated the need for integration-led automation. Workato has experienced such viral adoption because they are the first to combine enterprise-level integration and automation capabilities in a single platform with consumer ease of use,” said Pauline Yang, partner at Altimeter. "We are thrilled to be partnered with Vijay and the entire Workato team as they continue to transform how enterprises work."

“Our main challenges were the same challenges you see in most companies: rising costs, a growing IT backlog, and the need to effectively deal with risk. Now, two years into implementing Workato within our ML/NLP ecosystem, we’ve accelerated all of the work that IT does by over 30%. And although our company has grown rapidly, IT headcount and spend has remained flat,” said Wendy M. Pfeiffer, CIO at Nutanix. “Now that we’ve made headroom in our budget and within our existing team, we have the capacity for higher-level tasks. We’ve achieved 100% compliance with our SLAs, and our internal NPS scores regularly measure in the 90s. You can’t achieve this sustained performance by just staying the course. You have to use modern tools like Workato.”

About Workato

The leader in integration-led automation, Workato helps organizations work faster and smarter without compromising security and governance. Built for business and IT users, Workato is trusted by over 7,000 of the world's top brands like Broadcom, Intuit, Box, Autodesk, and HubSpot. Headquartered in Mountain View, Calif., Workato is backed by Altimeter Capital, Battery Ventures and Redpoint Ventures. For more information, visit www.workato.com or connect with us on social media:

1. Gartner. “Gartner Magic Quadrant for Enterprise Integration Platform as a Service.” Gartner. , 2020, https://www.gartner.com/en/documents/3990698/magic-quadrant-for-enterprise-integration-platform-as-a- .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye